Penile Arterial Revascularization
Penile arterial revascularization is a microsurgical bypass procedure restoring arterial inflow to the penis in men with pure arteriogenic erectile dysfunction caused by focal arterial occlusive disease — most commonly after blunt pelvic, perineal, or penile trauma. First described by Vaclav Michal in 1973, it remains the only potentially curative surgical treatment for arteriogenic ED, but is reserved for a highly selected patient population.[1][2] The contemporary standard donor is the inferior epigastric artery (IEA) anastomosed end-to-side to the dorsal penile artery (Michal II) — saphenous vein is not the standard donor for this procedure.
Dabaja 2014 found that nearly 50% of men initially identified as candidates were not properly diagnosed; repeat testing normalized findings in 73% of discrepant cases, disqualifying them from surgery.[3] Best outcomes are seen in young (< 55 yr), non-smoking, non-diabetic men with pure arteriogenic ED, < 2 vascular risk factors, and a history of focal pelvic / perineal / penile trauma.[4][5][6]
The AUA 2018 guideline gives a conditional recommendation, Grade C for penile arterial reconstruction in young men with focal pelvic / penile arterial occlusion who lack generalized vascular disease or veno-occlusive dysfunction.[7] The ICSM standard-operating-procedures statement (Sohn 2013) limits recommendations to Grade D (expert opinion) given the absence of RCTs.[8]
Pathophysiology and rationale
Arteriogenic ED in this context results from focal endothelial injury and stenosis / occlusion of the distal internal pudendal, common penile, or proximal cavernosal artery — distinct from generalized atherosclerotic disease.[2][1] Decreased arterial inflow lowers corporal oxygen tension, drives smooth-muscle atrophy, and produces secondary corporoveno-occlusive dysfunction.
The surgical goal is to bypass the occlusion and restore perfusion pressure to the cavernosal bodies via communicating branches between the dorsal and cavernosal arteries.[1][9]
Patient-selection criteria (locked)
| Criterion | Threshold |
|---|---|
| Age | < 55 years (best results < 50)[1][10] |
| Etiology | Pure arteriogenic — typically focal post-traumatic occlusion |
| Vascular risk factors | < 2 (smoking, diabetes, hypertension, hyperlipidemia, atherosclerosis)[4] |
| Atherosclerosis | Absent — generalized atherosclerotic disease is a contraindication[7] |
| Veno-occlusive function | Intact on DICC; absent corporal-fibrosis evidence[11][12] |
| Focal arterial lesion | Confirmed on selective internal pudendal arteriography (SIPA); concordant with duplex Doppler findings[3][13] |
Preoperative workup
| Step | Purpose |
|---|---|
| Duplex Doppler penile ultrasound (DUS) | Screens for arterial insufficiency (PSV < 25–30 cm/s suggests arterial inflow problem) and veno-occlusive dysfunction (EDV > 5 cm/s).[9][14] |
| Dynamic infusion cavernosometry / cavernosography (DICC) | Excludes corporoveno-occlusive dysfunction.[11][12] |
| Selective internal pudendal arteriography (SIPA) | Gold standard for defining focal arterial anatomy and identifying occlusion site. Mandatory because penile-arterial anatomic variants are present in up to 83% of patients.[14][15] |
| Concordance check | DUS / DICC findings must concord with SIPA; discrepancies prompt repeat testing.[3] |
Surgical techniques
All techniques use the inferior epigastric artery (IEA) as the donor.
| Technique | Description | Use |
|---|---|---|
| Michal I | Direct IEA → cavernosal artery anastomosis | Largely abandoned (poor results)[1] |
| Michal II (contemporary standard) | End-to-side IEA → dorsal penile artery; perfusion communicated to cavernosal artery via perforating branches | Standard of care[1][16][17] |
| Hauri | IEA → both dorsal penile artery and deep dorsal vein (arterializes venous system in addition to arterial bypass) | When communicating branches between dorsal and cavernosal arteries are present[11][18] |
| Furlow-Fisher modification of Virag V (FFV5) | IEA end-to-side to deep dorsal vein only — arterializes venous drainage | When no communicating branches identified or proximal common-penile-artery obstruction is present[11][16] |
| Mannheim triple anastomosis | IEA → dorsal artery + dorsal vein + additional anastomosis | Used in the German Mannheim series[4] |
Outcomes
| Series | n | Technique | Follow-up | Success | Notes |
|---|---|---|---|---|---|
| Cookson 1993[12] | 50 | Microsurgical bypass ± venous | 24 mo (median) | 88% excellent / improved; 67% excellent in pure arterial | Pure-arterial etiology significantly better than mixed |
| Manning 1998[4] | 62 | Virag / Hauri / Mannheim | 41 mo (mean) | 54% overall; 69% in age ≤ 50, < 2 risk factors | Age and risk factors strongly predict outcome |
| Kawanishi 2004[11] | 49 | Hauri / FFV5 | 5 yr | 67.5% subjective / 65.5% objective | No difference between techniques; strict selection |
| Kayıgil 2012[10] | 110 | Modified Furlow-Fisher | 73 mo (mean) | 63.6% at 5 yr; 92.8% with no risk factors | IIEF-5 7.3 → 16.8 |
| Zuckerman 2012[5] | 17 | IEA → dorsal artery | 3.1 yr (mean) | 82% (PFUI cohort) | Excellent results in post-traumatic patients |
The best outcomes are consistently seen in young, non-smoking, non-diabetic men with pure arteriogenic ED, < 2 risk factors, and a history of focal trauma.[4][19][11]
Complications
| Complication | Rate | Notes |
|---|---|---|
| Glans hyperemia / hypervascularization | 6–13% | Most characteristic; excessive arterial flow through dorsal artery to glans[4][19][11] |
| Shunt / anastomosis thrombosis | ~ 8% | [4] |
| Inguinal hernia | ~ 6.5% | Related to IEA harvest[4] |
| Penile edema | Common (transient) | Early postoperative[5] |
| Anastomotic hemorrhage | Rare | [11] |
| Scar contracture | Rare | [11] |
Endovascular alternatives
For older men with atherosclerotic arteriogenic ED — a population not eligible for microsurgical bypass — endovascular revascularization with drug-eluting stents has emerged as an alternative.
- Schönhofen 2021 registry n = 147 (mean age ~ 63): 54% achieved clinically meaningful improvement (≥ 4-point IIEF-6 increase) at mean 30 mo; 88.5% arterial patency in angiographic substudy.[20]
- Mohan 2025 long-term outcomes of drug-eluting stent implantation in atherosclerotic ED non-responding to PDE5i confirms durability.[21]
- Doppalapudi 2019 SR / meta of endovascular therapies: overall clinical success 63.2% for arterial insufficiency; complication rate 4.9%.[22]
- Diehm 2019 single-center experience identifies the patients most likely to benefit (focal lesion, PDE5i non-responder, post-pelvic-trauma anatomy).[23]
These approaches remain investigational and are best suited to patients who have failed PDE5i therapy.[23]
Guideline position
| Body | Position |
|---|---|
| AUA 2018[7] | Conditional Recommendation, Grade C — penile arterial reconstruction may be considered for young men with focal pelvic / penile arterial occlusion without generalized vascular disease or veno-occlusive dysfunction |
| ICSM SOP 2013 (Sohn)[8] | Grade D (expert opinion); no RCTs available |
Penile arterial revascularization is not a standard treatment in current guidelines — but may be offered in specialized centers for carefully selected patients.[2][8]
When to refer / when not to operate
- Refer: young man (< 55) with focal post-traumatic ED, PDE5i non-response, normal DICC, focal lesion on SIPA, < 2 vascular risk factors, no atherosclerosis.
- Do not operate: generalized atherosclerosis, > 2 risk factors, age > 55, veno-occlusive dysfunction on DICC, mixed-etiology ED, smoker who has not quit, diabetes.
- Endovascular alternative: consider for atherosclerotic ED in older PDE5i non-responders at experienced centers.[20][21]
Postoperative management
- Activity restriction. Avoid intercourse, masturbation, cycling, and strenuous exercise for 4–6 weeks to allow anastomosis healing.
- Postoperative duplex Doppler at 4–6 weeks to confirm patency.
- Anticoagulation / antiplatelet protocol per local microvascular service.
- PDE5i bridging during the early postoperative window to support tumescence-driven flow.
- PRO assessment. IIEF / IIEF-5 at baseline, 3 mo, 6 mo, 12 mo, with annual follow-up given known late attrition of patency.
- Smoking cessation is mandatory — all major series identified continued smoking as the strongest predictor of failure.[4][10]
See Also
- Erectile Dysfunction Atlas (04j ED database)
- Erectile Dysfunction (clinical condition)
- Pelvic Fracture Urethral Injury (PFUI) — the trauma context that produces most candidates
- PDE5 Inhibitors (pharmacology hub)
- Psychosexual Therapy
References
1. Dicks B, Bastuba M, Goldstein I. Penile revascularization — contemporary update. Asian J Androl. 2013;15(1):5–9. doi:10.1038/aja.2012.146
2. Hsieh CH, Hsu GL, Chang SJ, et al. Surgical niche for the treatment of erectile dysfunction. Int J Urol. 2020;27(2):117–133. doi:10.1111/iju.14157
3. Dabaja AA, Teloken P, Mulhall JP. A critical analysis of candidacy for penile revascularization. J Sex Med. 2014;11(9):2327–2332. doi:10.1111/jsm.12594
4. Manning M, Jünemann KP, Scheepe JR, et al. Long-term followup and selection criteria for penile revascularization in erectile failure. J Urol. 1998;160(5):1680–1684.
5. Zuckerman JM, McCammon KA, Tisdale BE, et al. Outcome of penile revascularization for arteriogenic erectile dysfunction after pelvic fracture urethral injuries. Urology. 2012;80(6):1369–1373. doi:10.1016/j.urology.2012.07.059
6. Sarramon JP, Bertrand N, Malavaud B, Rischmann P. Microrevascularisation of the penis in vascular impotence. Int J Impot Res. 1997;9(3):127–133. doi:10.1038/sj.ijir.3900287
7. Burnett AL, Nehra A, Breau RH, et al. Erectile dysfunction: AUA guideline. J Urol. 2018;200(3):633–641. doi:10.1016/j.juro.2018.05.004
8. Sohn M, Hatzinger M, Goldstein I, Krishnamurti S. Standard operating procedures for vascular surgery in erectile dysfunction: revascularization and venous procedures. J Sex Med. 2013;10(1):172–179. doi:10.1111/j.1743-6109.2012.02997.x
9. Wegner HE, Andresen R, Knispel HH, Banzer D, Miller K. Evaluation of penile arteries with color-coded duplex sonography. J Urol. 1995;153(5):1469–1471. doi:10.1016/s0022-5347(01)67435-4
10. Kayıgil O, Okulu E, Aldemir M, Onen E. Penile revascularization in vasculogenic erectile dysfunction: long-term follow-up. BJU Int. 2012;109(1):109–115. doi:10.1111/j.1464-410X.2011.10293.x
11. Kawanishi Y, Kimura K, Nakanishi R, Kojima K, Numata A. Penile revascularization surgery for arteriogenic erectile dysfunction: the long-term efficacy rate calculated by survival analysis. BJU Int. 2004;94(3):361–368. doi:10.1111/j.1464-410X.2004.04867.x
12. Cookson MS, Phillips DL, Huff ME, Fitch WP. Analysis of microsurgical penile revascularization results by etiology of impotence. J Urol. 1993;149(5 Pt 2):1308–1312. doi:10.1016/s0022-5347(17)36376-0
13. Wahl SI, Rubin MB, Bakal CW. Radiologic evaluation of penile arterial anatomy in arteriogenic impotence. Int J Impot Res. 1997;9(2):93–97. doi:10.1038/sj.ijir.3900273
14. Jarow JP, Pugh VW, Routh WD, Dyer RB. Comparison of penile duplex ultrasonography to pudendal arteriography. Variant penile arterial anatomy affects interpretation of duplex ultrasonography. Invest Radiol. 1993;28(9):806–810.
15. Liu LC, Liu LH, Lin GJ, et al. Penile revascularization: report of 4 cases. J Formos Med Assoc. 1990;89(10):930–933.
16. Sarramon JP, Bertrand N, Malavaud B, Rischmann P. Microrevascularisation of the penis in vascular impotence. Int J Impot Res. 1997;9(3):127–133. doi:10.1038/sj.ijir.3900287
17. Löbelenz M, Jünemann KP, Köhrmann KU, et al. Penile revascularization in nonresponders to intracavernous injections using a modified microsurgical technique. Eur Urol. 1992;21(2):120–125. doi:10.1159/000474816
18. Hauri D. Penile revascularization surgery in erectile dysfunction. Urol Int. 2003;70(3):165–171. (Hauri technique original description)
19. Kayıgil O, Okulu E, Aldemir M, Onen E. Penile revascularization in vasculogenic erectile dysfunction (ED): long-term follow-up. BJU Int. 2012;109(1):109–115. doi:10.1111/j.1464-410X.2011.10293.x
20. Schönhofen J, Räber L, Knöchel J, et al. Endovascular therapy for arteriogenic erectile dysfunction with a novel sirolimus-eluting stent. J Sex Med. 2021;18(2):315–326. doi:10.1016/j.jsxm.2020.10.021
21. Mohan V, Schönhofen J, Hoppe H, et al. Long-term outcomes of drug-eluting stent implantation for patients with atherosclerotic erectile dysfunction not responding to PDE-5 inhibitors. J Endovasc Ther. 2025;32(3):720–729. doi:10.1177/15266028231183775
22. Doppalapudi SK, Wajswol E, Shukla PA, et al. Endovascular therapy for vasculogenic erectile dysfunction: a systematic review and meta-analysis of arterial and venous therapies. J Vasc Interv Radiol. 2019;30(8):1251–1258.e2. doi:10.1016/j.jvir.2019.01.024
23. Diehm N, Marggi S, Ueki Y, et al. Endovascular therapy for erectile dysfunction — who benefits most? Insights from a single-center experience. J Endovasc Ther. 2019;26(2):181–190. doi:10.1177/1526602819829903